Getting Rid of Weakness in the ICU: An Updated Approach to the Acute Management of Myasthenia Gravis and Guillain-Barré Syndrome
暂无分享,去创建一个
[1] M. Freimer. Faculty Opinions recommendation of International consensus guidance for management of myasthenia gravis: Executive summary. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[2] Emmanuel Fournier,et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study , 2016, The Lancet.
[3] J. Finsterer,et al. Stress from myasthenic crisis triggers Takotsubo (broken heart) syndrome. , 2016, International journal of cardiology.
[4] J. Fernández,et al. Myasthenic Crisis in an Elderly Patient with Positive Antibodies against Acetylcholine and Anti-MuSK, Successfully Treated with Noninvasive Mechanical Ventilation , 2015, Case reports in critical care.
[5] A. Rabinstein. Acute neuromuscular respiratory failure , 2015, Journal of the Neurological Sciences.
[6] A. Rabinstein,et al. Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome? , 2015, Arquivos de neuro-psiquiatria.
[7] I. Jericó,et al. Myasthenia gravis: descriptive analysis of life‐threatening events in a recent nationwide registry , 2015, European journal of neurology.
[8] B. Demaerschalk,et al. IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence? A Critically Appraised Topic , 2015, The neurologist.
[9] A. Berkowitz,et al. Posterior reversible encephalopathy syndrome in Guillain-Barré syndrome , 2015, Journal of Clinical Neuroscience.
[10] E. McNicol,et al. Pharmacological treatment for pain in Guillain-Barré syndrome. , 2015, The Cochrane database of systematic reviews.
[11] J. Lünemann,et al. Intravenous immunoglobulin in neurology—mode of action and clinical efficacy , 2015, Nature Reviews Neurology.
[12] G. Cutter,et al. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? , 2014, Muscle & nerve.
[13] A. Engeland,et al. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries , 2014, Acta neurologica Scandinavica. Supplementum.
[14] Kangding Liu,et al. Predictors of outcome of myasthenic crisis , 2014, Neurological Sciences.
[15] H. Ebadi,et al. Safety of plasma exchange therapy in patients with myasthenia gravis , 2013, Muscle & nerve.
[16] M. Uchino,et al. Myasthenic crisis patients who require intensive care unit management , 2012, Muscle & nerve.
[17] A. Uncini,et al. Outcome and its predictors in Guillain–Barré syndrome , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[18] D. Orlikowski,et al. Vital Capacity Versus Maximal Inspiratory Pressure in Patients with Guillain–Barré Syndrome and Myasthenia Gravis , 2012, Neurocritical Care.
[19] Vibhav Bansal,et al. Broken heart syndrome in myasthenia gravis , 2011, Muscle & nerve.
[20] R. Holloway,et al. Plasma Exchange versus Intravenous Immunoglobulin for Myasthenia Gravis Crisis: An Acute Hospital Cost Comparison Study , 2011, Journal of clinical neuromuscular disease.
[21] D. Sanders,et al. Anti‐musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts , 2011, Muscle & nerve.
[22] V. Bril,et al. Comparison of IVIg and PLEX in patients with myasthenia gravis , 2011, Neurology.
[23] Hester F. Lingsma,et al. Early recognition of poor prognosis in Guillain-Barré syndrome , 2011, Neurology.
[24] M. Musthafa,et al. Guillain-Barré syndrome and SIADH , 2011, Neurology.
[25] Hester F. Lingsma,et al. Prediction of respiratory insufficiency in Guillain‐Barré syndrome , 2010, Annals of neurology.
[26] A. McGrogan,et al. The Incidence of Myasthenia Gravis: A Systematic Literature Review , 2010, Neuroepidemiology.
[27] N. Gilhus,et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders , 2006, European journal of neurology.
[28] M. Benatar. Pearls: myasthenia. , 2010, Seminars in neurology.
[29] A. Alshekhlee,et al. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals , 2009, Neurology.
[30] Pan‐Chyr Yang,et al. The Role of Non-invasive Ventilation and Factors Predicting Extubation Outcome in Myasthenic Crisis , 2009, Neurocritical care.
[31] A. McGrogan,et al. The Epidemiology of Guillain-Barré Syndrome Worldwide , 2008, Neuroepidemiology.
[32] E. Wijdicks,et al. Noninvasive ventilation in myasthenic crisis. , 2008, Archives of neurology.
[33] C. Bai,et al. MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravis , 2007, Journal of the Neurological Sciences.
[34] D. Annane,et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. , 2007, Brain : a journal of neurology.
[35] E. Steyerberg,et al. A clinical prognostic scoring system for Guillain-Barré syndrome , 2007, The Lancet Neurology.
[36] E. Wijdicks,et al. Mechanical ventilation in patients with Guillain-Barré syndrome. , 2006, Respiratory care.
[37] N. Gilhus,et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders , 2006, European journal of neurology.
[38] A. Malhotra,et al. Factors predicting extubation success in patients with Guillain-Barré syndrome , 2006, Neurocritical care.
[39] H. Diener,et al. Long-term outcome of Guillain-Barré syndrome , 2006, Neurocritical care.
[40] R. Hughes,et al. Intravenous immunoglobulin for Guillain-Barré syndrome. , 2006, The Cochrane database of systematic reviews.
[41] R. Agarwal,et al. Noninvasive ventilation in acute neuromuscular respiratory failure due to myasthenic crisis: case report and review of literature , 2005, Emergency Medicine Journal.
[42] D. Orlikowski,et al. Significance of phrenic nerve electrophysiological abnormalities in Guillain–Barré syndrome , 2005, Neurology.
[43] F. Bolgert,et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. , 2005, Archives of neurology.
[44] Richard J Barohn,et al. Supportive care for patients with Guillain-Barré syndrome. , 2005, Archives of neurology.
[45] Abhishek Kumar,et al. The Comparative Evaluation of Gabapentin and Carbamazepine for Pain Management in Guillain-Barré Syndrome Patients in the Intensive Care Unit , 2005, Anesthesia and analgesia.
[46] J. Raphaël,et al. [Guillain-Barré syndrome]. , 2005, La Revue du praticien.
[47] M. Mori,et al. Recovery patterns and long term prognosis for axonal Guillain–Barré syndrome , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[48] J. Chevrolet,et al. The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis , 1995, Intensive Care Medicine.
[49] A. Rabinstein,et al. Risk of extubation failure in patients with myasthenic crisis , 2005, Neurocritical care.
[50] A. Moayyeri,et al. Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: A 17-year experience , 2004, BMC neurology.
[51] R. Schnaar,et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. , 2004, Brain : a journal of neurology.
[52] I. Kanazawa,et al. Anti-GQ1b antibody as a factor predictive of mechanical ventilation in Guillain-Barré syndrome , 2004, Neurology.
[53] V. Juel. Myasthenia gravis: management of myasthenic crisis and perioperative care. , 2004, Seminars in neurology.
[54] D. Orlikowski,et al. Respiratory dysfunction in guillain-barré syndrome , 2004, Neurocritical care.
[55] A. Qureshi,et al. Myasthenic crisis , 2004, Current treatment options in neurology.
[56] H. Willison,et al. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. , 2003, Brain : a journal of neurology.
[57] P. Tonali,et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. , 2003, Brain : a journal of neurology.
[58] M. Mori,et al. Differences in patterns of progression in demyelinating and axonal Guillain–Barré syndromes , 2003, Neurology.
[59] A. Vincent,et al. Clinical aspects of MuSK antibody positive seronegative MG , 2003, Neurology.
[60] S. Chevret,et al. Early predictors of mechanical ventilation in Guillain-Barré syndrome , 2003, Critical care medicine.
[61] S. Chevret,et al. Intravenous immunoglobulin for myasthenia gravis. , 2003, The Cochrane database of systematic reviews.
[62] E. Wijdicks,et al. BiPAP in acute respiratory failure due to myasthenic crisis may prevent intubation , 2002, Neurology.
[63] D. Sanders,et al. On the Concept of Myasthenic Crisis , 2002, Journal of clinical neuromuscular disease.
[64] J. Keesey,et al. “Crisis” in myasthenia gravis: An historical perspective , 2002, Muscle & nerve.
[65] S. Chevret,et al. Plasma exchange for myasthenia gravis. , 2002, The Cochrane database of systematic reviews.
[66] S. Vorstrup,et al. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. , 2001, Artificial organs.
[67] M. Camilleri,et al. Adynamic ileus in severe Guillain–Barré syndrome , 2001, Muscle & nerve.
[68] E. Wijdicks,et al. Anticipating mechanical ventilation in Guillain-Barré syndrome. , 2001, Archives of neurology.
[69] H. Hartung,et al. Preceding infections, immune factors, and outcome in Guillain–Barré syndrome , 2001, Neurology.
[70] P. Tonali,et al. Therapeutic apheresis in myasthenia gravis. , 2000, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[71] G. Pfeiffer,et al. Indicators of dysautonomia in severe Guillain-Barré syndrome , 1999, Journal of Neurology.
[72] J. Ulatowski,et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis , 1999, Neurology.
[73] R. Hughes,et al. The Italian Guillain-Barré Study Group. The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients. , 1998, Brain : a journal of neurology.
[74] E. Wijdicks,et al. Respiratory management in acute neurologic illness , 1998, Neurology.
[75] H. Kwiecinski. [Disorders of neuromuscular transmission]. , 1998, Neurologia i neurochirurgia polska.
[76] I. Wirguin,et al. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome , 1997, The Lancet.
[77] S. Chevret,et al. Clinical trial of plasma exchange and high‐dose intravenous immunoglobulin in myasthenia gravis , 1997 .
[78] B. Pentland,et al. Pain in the Guillain-Barré syndrome: a clinical review , 1994, Pain.
[79] D. Zochodne. Autonomic involvement in Guillain–Barre syndrome: A review , 1994, Muscle & nerve.
[80] G. Mckhann,et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China , 1991, The Lancet.
[81] D. Cornblath,et al. Assessment of current diagnostic criteria for Guillain‐Barré syndrome , 1990, Annals of neurology.
[82] R. Hughes,et al. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. , 1988, Journal of neurology, neurosurgery, and psychiatry.
[83] G. Mckhann,et al. Motor conduction studies in guillain‐barré syndrome: Description and prognostic value , 1988, Annals of neurology.
[84] D. Grob,et al. The Course of Myasthenia Gravis and Therapies Affecting Outcome a , 1987, Annals of the New York Academy of Sciences.
[85] K. A. McCarter. Plasma Exchange in Guillain-Barré Syndrome , 1982, Nursing times.
[86] D. Younger,et al. ASPECTS OF THE NATURAL HISTORY OF MYASTHENIA GRAVIS: CRISIS AND DEATH , 1981, Annals of the New York Academy of Sciences.
[87] N. Murray,et al. The sural sensory action potential in Guillain-Barré syndrome. , 1980, Muscle & nerve.
[88] R. Hughes,et al. CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHY , 1978, The Lancet.
[89] D. Elmqvist. Myasthenia Gravis , 1975, The Lancet.
[90] M. Fisher. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). , 1956, The New England journal of medicine.